Werewolf Therapeutics, Inc.

Once seen as the next big thing in cancer, cytokine-based therapies lost their shine after numerous trial flops, but Synthekine is among a number of companies that believe they can succeed with a ne

Venture capital fundraising by biopharmaceutical companies plunged in the fourth quarter to $4.3bn, down from $6.2bn in the third quarter and below the $5.7bn raised in Q4 of 2022, according to the la

Jazz Pharmaceuticals plc has acquired near-global rights to a promising narcolepsy candidate from Japan’s Sumitomo Pharmaceuticals Europe Ltd. , paying $50m upfront at a time when some of its bigges

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Jazz Moves Into IO With Engineered IFN⍺